274 related articles for article (PubMed ID: 31332046)
1. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
Bishop MR; Maziarz RT; Waller EK; Jäger U; Westin JR; McGuirk JP; Fleury I; Holte H; Borchmann P; Del Corral C; Tiwari R; Anak Ö; Awasthi R; Pacaud L; Romanov VV; Schuster SJ
Blood Adv; 2019 Jul; 3(14):2230-2236. PubMed ID: 31332046
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Goto H; Makita S; Kato K; Tokushige K; Fujita T; Akashi K; Izutsu K; Teshima T
Int J Clin Oncol; 2020 Sep; 25(9):1736-1743. PubMed ID: 32448949
[TBL] [Abstract][Full Text] [Related]
4. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
5. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.
Schuster SJ; Maziarz RT; Rusch ES; Li J; Signorovitch JE; Romanov VV; Locke FL; Maloney DG
Blood Adv; 2020 Apr; 4(7):1432-1439. PubMed ID: 32271899
[TBL] [Abstract][Full Text] [Related]
6. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
[No Abstract] [Full Text] [Related]
7. Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Fujita T; Yang H; Chai X; Qi CZ; Liu Q; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Jun; 27(6):506.e1-506.e10. PubMed ID: 33823168
[TBL] [Abstract][Full Text] [Related]
8. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Awasthi R; Pacaud L; Waldron E; Tam CS; Jäger U; Borchmann P; Jaglowski S; Foley SR; van Besien K; Wagner-Johnston ND; Kersten MJ; Schuster SJ; Salles G; Maziarz RT; Anak Ö; Del Corral C; Chu J; Gershgorin I; Pruteanu-Malinici I; Chakraborty A; Mueller KT; Waller EK
Blood Adv; 2020 Feb; 4(3):560-572. PubMed ID: 32045475
[TBL] [Abstract][Full Text] [Related]
9. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
Cher BP; Gan KY; Aziz MIA; Lin L; Hwang WYK; Poon LM; Ng K
J Med Econ; 2020 Nov; 23(11):1321-1329. PubMed ID: 32780608
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Maziarz RT; Waller EK; Jaeger U; Fleury I; McGuirk J; Holte H; Jaglowski S; Schuster SJ; Bishop MR; Westin JR; Mielke S; Teshima T; Bachanova V; Foley SR; Borchmann P; Salles GA; Zhang J; Tiwari R; Pacaud LB; Ma Q; Tam CS
Blood Adv; 2020 Feb; 4(4):629-637. PubMed ID: 32074277
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
12. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR
N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798
[TBL] [Abstract][Full Text] [Related]
13. [Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y; Kanemasa Y; Sasaki Y; Hayashi Y; Mino M; Kato C; Sakai S; Ohigashi A; Kanbara Y; Morita Y; Tamura T; Atsuta Y; Konuma R; Nakamura S; Wada A; Okuya T; Kageyama A; Murakami D; Nakashima S; Uchibori Y; Onai D; Hamamura A; Nishijima A; Omuro Y; Shingai N; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Ohashi K; Doki N; Okuyama Y; Shimoyama T
Rinsho Ketsueki; 2022; 63(10):1363-1372. PubMed ID: 36351641
[TBL] [Abstract][Full Text] [Related]
14. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Thudium Mueller K; Grupp SA; Maude SL; Levine JE; Pulsipher MA; Boyer MW; August KJ; Myers GD; Tam CS; Jaeger U; Foley SR; Borchmann P; Schuster SJ; Waller EK; Awasthi R; Potthoff B; Warren A; Waldron ER; McBlane F; Chassot-Agostinho A; Laetsch TW
Blood Adv; 2021 Dec; 5(23):4980-4991. PubMed ID: 34432863
[TBL] [Abstract][Full Text] [Related]
15. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.
Maziarz RT; Zhang J; Yang H; Chai X; Yuan C; Schwarz E; Jakovac M; Martinez-Prieto M; Agarwal A; Degtyarev E; Tam C; Salles G
Blood Adv; 2022 Apr; 6(8):2536-2547. PubMed ID: 35030634
[TBL] [Abstract][Full Text] [Related]
16. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
Eigendorff F; Filimonova I; Scholl S; Sayer-Klink A; Rummler S; Kunert C; Pietschmann K; Wittig A; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2024 May; 150(5):224. PubMed ID: 38693452
[TBL] [Abstract][Full Text] [Related]
17. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
[TBL] [Abstract][Full Text] [Related]
18. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Iacoboni G; Villacampa G; Martinez-Cibrian N; Bailén R; Lopez Corral L; Sanchez JM; Guerreiro M; Caballero AC; Mussetti A; Sancho JM; Hernani R; Abrisqueta P; Solano C; Sureda A; Briones J; Martin Garcia-Sancho A; Kwon M; Reguera-Ortega JL; Barba P;
Cancer Med; 2021 May; 10(10):3214-3223. PubMed ID: 33932100
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H; Kitawaki T; Fujii N; Kato K; Onishi Y; Fukuhara N; Yamauchi T; Toratani K; Kobayashi H; Yoshida S; Shimo M; Onodera K; Senjo H; Onozawa M; Hirata K; Yokota I; Teshima T
Int J Clin Oncol; 2023 Jun; 28(6):816-826. PubMed ID: 37071252
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.
Jaeger U; Worel N; McGuirk JP; Riedell PA; Fleury I; Du Y; Han X; Pearson D; Redondo S; Waller EK
Blood Adv; 2023 Jun; 7(11):2283-2286. PubMed ID: 36044388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]